We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Prometic Life Sciences has signed a memorandum of terms with Shenzhen Royal Asset Management (SRAM) to establish a joint venture (JV) for the development, manufacture and commercialisation of three drug candidates, PBI-4050, PBI-4547 and PBI-4425, in Chin